Ebola Outbreak Could Cost $32 Billion — World Bank
The World Bank has put out an estimate of what a wider outbreak of Ebola could cost: $32 billion.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 281Unilife Finds Second Wave
ThinkstockUnilife Corporation (NASDAQ: UNIS) is riding the wave Wednesday as it watches its shares surf into the close. While this stock was up over 50% on Monday, a second wave is being made by…
Histogenics Files for IPO
Histogenics Corp. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
Ebola Drug Stocks React Wildly to Dallas Patient Death
The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola drugs might not be a cure-all for patients.
How Ebola Could Cost the World $32 Billion by End of 2015
The World Bank projects what the potential costs could be if the Ebola epidemic were to significantly infect people in neighboring countries with much larger economies.
AutoGenomics Files for IPO — Sorry, Files Again
AutoGenomics has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
INC Research Files for IPO
INC Research Holdings Inc. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
Reality Sets in for Ebola Drug Hopefuls
Tekmira Pharmaceuticals downgrade also drags down Sarepta Therapeutics and BioCryst Pharmaceuticals.
Alcobra Loses Focus in ADHD Trial for FDA Approval
Alcobra recently posted news of an FDA trial and its shares traded down about 50% Monday morning.
Chimerix Wants Its Piece of the Ebola Pie
Chimerix has announced that its lead drug candidate has been provided for potential use in patients with Ebola virus disease.
Analyst Still Sees Zogenix Potentially Doubling
Oppenheimer's official rating on Zogenix remains Outperform, but what stands out is that the $2.50 price target implies that shares can more than double.
Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
Biotech Company FibroGen Files for IPO
Biotech company FibroGen filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.
Major Fallout Stocks After Confirmed Ebola Case in United States
With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides of the Ebola story.
Reaction to Confirmed Ebola Case in U.S. — UPDATED
News has hit of the first confirmed Ebola case in the United States. Companies involved in potential drugs for Ebola have seen their shares pop.